Navigation Links
Hemophilia Pipeline Overview - Once-a-week prophylaxis may soon become a reality
Date:12/13/2012

recombinant PEGylated factor IX; Baxter)

CSL654 (rFIX-albumin fusion; CSL Behring)

BIIB 029 (rFIXFc; Biogen Idec)

NN7999 (rFIX, glycoPEGylated; Novo Nordisk)

Clinical and commercial attractiveness for key hemophilia B pipeline products

Bibliography

Journal articles and online sources

Appendix

Methodology

Datamonitor drug assessment for clinical and commercial attractiveness

TABLES

Table: Clinical pipeline key drugs for hemophilia A and B, November 2012

Table: Kogenate FS (recombinant Factor VIII; Bayer) – drug profile, 2012

Table: Kogenate FS (recombinant Factor VIII; Bayer) – drug profile, 2012

Table: Kogenate FS (rFVIII; Bayer) and BeneFIX (rFIX; Pfizer) vs the target product profile in previously treated patients, 2012

Table: Key events in the clinical development of NN7008 (turoctocog alfa; Novo Nordisk), 2012

Table: Key events in the clinical development of BIIB 031 (rFVIIIFc; Biogen Idec), 2012

Table: Key events for the clinical development of NN7088 (Novo Nordisk), 2012

Table: Key events for the clinical development of BAY-94-9027 (Bayer), 2012

Table: Key events for the clinical development of BAX 326 (Baxter), 2012

Table: Key events for the clinical development of CSL654 (CSL Behring), 2012

Table: Key events for the clinical development of BIIB 029 (rFIXFc; Biogen Idec), 2012

Table: Key events for the clinical development of NN7999 (Novo Nordisk), 2012

FIGURES

Figure: Clinical and commercial attractiveness for key hemophilia A pipeline drugs vs comparator Kogenate FS (rFVIII; Bayer), 2012

Figure: Breakdown of clinical and commercial attractiveness attributes for key hemophilia A pipeline drugs, 2012

Figure: Launch timeline for key hemophilia A pipeline drugs, 2012

Figure: Clinical and commercial attractiveness for key hemophilia B pipeline drugs vs comparator B
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novo Nordisk introduces HemaGo, a mobile application to track hemophilia treatment, bleeding episodes and life events
2. Bayers Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community
3. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
4. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
5. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
6. Bausch + Lomb Product, Platform and Pipeline Innovations on Display at the Annual Meeting of the American Academy of Ophthalmology
7. Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
8. Neurostimulation Devices Market to 2018 - Technological Advances and Robust Pipeline with Multi-Indication Potential and Non-Invasive Therapies to Drive Growth
9. Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets
10. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
11. Biopsy Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... October 30, 2014 ... the addition of the  "Process Validation in the ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key ... Risk Based Approach to Process Validation for Pharmaceutical ... FDA Process Validation Guidance ...
(Date:10/31/2014)... 31, 2014 Though therapies are in their ... to show an annual increase of 16.2% over the ... $1 billion, according to Kalorama Information,s report, Stem ... cell therapeutics that have gained or are expected to ... drug developers tackle ever more complicated conditions, stem cell ...
(Date:10/30/2014)... 2014  Misonix, Inc. (NASDAQ: MSON ), ... and markets innovative therapeutic ultrasonic instruments for spine surgery, ... will report financial results for the first quarter fiscal ... has scheduled a conference call that same day, Thursday, ... the results. Interested parties can access ...
Breaking Medicine Technology:Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Report: Stem Cell Technologies Market Growing 2Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2
... SAN and NYSE: SNY) announced today that ... (dronedarone), a potential therapy,for the treatment of ... the risk of cardiovascular hospitalizations or death ... (p=0.00000002), meeting the study,primary endpoint. The ATHENA ...
... Switzerland, May 15 Ergonex Pharma today,announced that ... has,granted orphan drug designation to Terguride for the ... being evaluated for PAH,in a pivotal Phase II ... orphan drug designation to Terguride for PAH,encourages and ...
Cached Medicine Technology:Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2
(Date:10/31/2014)... engineers have invented a lab device to give cancer ... way that tumor cells spread through the body, causing ... light on precisely how tumor cells travel, the device ... , The inventors, from the university,s Whiting School of ... and images from their new system recently in the ...
(Date:10/31/2014)... Urban Hydroponics, Inc. (OTCQB:URHY), a Nevada ... has signed a Binding Letter of Intent (LOI) to ... sector - Urban Cultivator Inc. (“Urban Cultivator”), BC Northern ... Inc. (“W3 Metal” and together with Urban Cultivator and ... the LOI and an earlier non-binding term sheet, Urban ...
(Date:10/31/2014)... In an effort to expand services and ... announced he will soon offer orthodontics at his Oral & ... November. , To build upon the high degree of ... has become known for, Dr. Jamali is welcoming an orthodontist ... learning institutions as UCLA, Stanford and UCSF. He added that ...
(Date:10/31/2014)... 31, 2014 Uniwigs.com newly arrived flip ... new model can comfortably attach itself around people’s heads with ... new generation of flip-in extensions comes with adjustable loops, which ... wire part and customers can now adjust the wire to ... When people apply this new generation of flip ins, they ...
(Date:10/31/2014)... simple steps can help make this weekend,s time change easier ... the end of Daylight Saving Time in the fall is ... spring. The main reason is because we gain an hour ... director of the Center for Sleep Medicine at Northern Westchester ... release. The many Americans who are sleep-deprived should go ...
Breaking Medicine News(10 mins):Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 3Health News:UniWigs Unveiles New Generation of Flip In Hair Extensions 2Health News:Make the Most of This Weekend's Time Change 2
... 50 Percent of Members Say They Don,t Fully Understand the Details ... of Their ... plan,performance varies widely among some insurers across the U.S., yet,contacting plan ... more consistent and positive satisfaction ratings,more renewal business and additional sales ...
... Many people struggle with,compulsive eating and other eating ... too often, they don,t know where to start. Overeaters,Anonymous ... more about its,Twelve-Step path to recovery., Through a ... OA,s program can now download information and personal,compelling stories ...
... the nation,s,leading supplier of replacement medical repair parts ... Health to become their primary,supplier of medical replacement ... organizations and will provide significant,synergies to both organizations., ... health systems and we are,justifiably proud to count ...
... very aggressive disorder. A report published on March 14, ... a case. A 41-year-old man presented with a 6-month ... polypoid tumor of the lower rectum was found at ... Dissemination studies did not show any metastases. He underwent ...
... AMDL, Inc. (Amex:,ADL), headquartered in Tustin, California, ... is a vertically integrated specialty,pharmaceutical company. In ... the Company engages in the research,development, manufacturing, ... cosmetic products., AMDL today announced that ...
... More than 6.1 million,Americans are covered by Health ... since last year, a new census released today,by ... authorized,starting in January 2004. Since then, AHIP has ... the HSA plan market., (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ...
Cached Medicine News:Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 2Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 3Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 4Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 5Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 6Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 7Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 8Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 9Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 10Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 11Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 12Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 13Health News:PartsSource & Adventist Health Sign Agreement for Parts Procurement 2Health News:AMDL Signs MOU for 200 Store Distribution Arrangements for Goodnak Product Line 2Health News:More Than Six Million Enrolled in Health Savings Account Plans 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: